Green Thumb Industries - GTBIF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $39.88
  • Forecasted Upside: 253.19%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.29
▼ -0.07 (-0.62%)

This chart shows the closing price for GTBIF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Green Thumb Industries Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTBIF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTBIF

Analyst Price Target is $39.88
▲ +253.19% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Green Thumb Industries in the last 3 months. The average price target is $39.88, with a high forecast of $71.50 and a low forecast of $16.00. The average price target represents a 253.19% upside from the last price of $11.29.

This chart shows the closing price for GTBIF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Green Thumb Industries. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/10/2024WedbushBoost TargetOutperform ➝ Outperform$15.00 ➝ $16.00
5/9/2024Needham & Company LLCBoost TargetBuy ➝ Buy$15.50 ➝ $17.00
2/29/2024Needham & Company LLCBoost TargetBuy ➝ Buy$11.00 ➝ $15.50
11/28/2023Atb Cap MarketsReiterated RatingOutperform
8/9/2023Alliance Global PartnersLower TargetC$21.00 ➝ C$19.00
7/31/2023Stifel NicolausLower TargetC$30.00 ➝ C$22.00
3/3/2023WedbushLower Target$18.00 ➝ $12.00
3/1/2023BenchmarkReiterated RatingBuy$18.00
3/1/2023Cantor FitzgeraldLower TargetOverweight$32.00 ➝ $30.00
2/27/2023Piper SandlerDowngradeOverweight ➝ Neutral
2/8/2023Stifel NicolausLower TargetC$31.00 ➝ C$30.00
12/1/2022WedbushInitiated CoverageOutperform$18.00
11/3/2022Cantor FitzgeraldBoost TargetOverweight$32.00 ➝ $36.00
11/3/2022Stifel NicolausBoost TargetC$30.50 ➝ C$31.00
10/28/2022Cantor FitzgeraldBoost TargetOverweight$31.00 ➝ $32.00
10/28/2022BTIG ResearchReiterated RatingBuy
8/4/2022Alliance Global PartnersLower TargetC$25.00
8/4/2022Cantor FitzgeraldLower TargetOverweight$39.00 ➝ $31.00
8/4/2022CowenLower Target$45.00 ➝ $20.00
7/22/2022Seaport Res PtnReiterated RatingBuy
7/19/2022Roth CapitalReiterated RatingBuy
5/5/2022Echelon Wealth PartnersReiterated RatingBuy
5/5/2022Alliance Global PartnersLower TargetC$40.00 ➝ C$38.00
5/5/2022Craig HallumLower Target$35.00 ➝ $25.00
5/5/2022Needham & Company LLCLower Target$33.00 ➝ $26.00
3/2/2022Canaccord Genuity GroupLower TargetC$46.00 ➝ C$43.00
3/2/2022Stifel NicolausLower TargetC$80.00 ➝ C$73.00
3/2/2022Needham & Company LLCLower TargetBuy$36.00 ➝ $33.00
3/1/2022BenchmarkLower Target$45.00 ➝ $30.00
2/28/2022Craig HallumLower Target$50.00 ➝ $40.00
2/25/2022Cantor FitzgeraldLower TargetOverweight$54.00 ➝ $41.00
1/7/2022Wolfe ResearchInitiated CoverageOutperform
12/30/2021Echelon Wealth PartnersReiterated RatingBuy$55.00
11/11/2021Craig HallumLower TargetBuy$60.00 ➝ $50.00
11/11/2021Cantor FitzgeraldBoost TargetOverweight$38.00 ➝ $54.00
11/3/2021Cantor FitzgeraldLower TargetOverweight$46.00 ➝ $38.00
11/2/2021Needham & Company LLCLower TargetBuy$47.25 ➝ $36.00
11/1/2021Stifel NicolausBoost TargetBuyC$71.50 ➝ C$80.00
8/12/2021BTIG ResearchBoost TargetBuyC$73.00 ➝ C$77.00
8/12/2021Cantor FitzgeraldBoost TargetOverweight$43.50 ➝ $46.00
7/7/2021Jefferies Financial GroupInitiated CoverageBuy$70.00
5/13/2021Cantor FitzgeraldReiterated RatingBuy$43.00
3/31/2021Needham & Company LLCReiterated RatingBuy$47.25
3/18/2021Craig HallumBoost Target$55.00 ➝ $60.00
3/18/2021Alliance Global PartnersBoost TargetBuy$50.00 ➝ $55.00
3/18/2021Piper SandlerBoost TargetOverweight$35.00 ➝ $40.00
3/18/2021Roth CapitalBoost TargetBuy$40.00 ➝ $45.00
3/18/2021Needham & Company LLCBoost TargetBuy$46.75 ➝ $47.25
3/18/2021CowenBoost TargetTop Pick ➝ Outperform$30.00 ➝ $45.00
3/18/2021Cantor FitzgeraldLower TargetOverweight$62.00 ➝ $50.00
3/11/2021Needham & Company LLCReiterated RatingBuy$46.75
3/8/2021BTIG ResearchInitiated CoverageBuy
2/25/2021Stifel NicolausBoost TargetBuy$46.00 ➝ $71.50
2/11/2021Cantor FitzgeraldBoost TargetOverweight$35.00 ➝ $62.00
1/20/2021Roth CapitalBoost TargetBuy$29.00 ➝ $40.00
1/19/2021Needham & Company LLCBoost TargetBuy$39.00 ➝ $46.75
1/13/2021Echelon Wealth PartnersReiterated RatingBuy$38.00
1/6/2021Needham & Company LLCReiterated RatingBuy$39.00
11/12/2020Stifel NicolausBoost TargetBuy$44.00 ➝ $46.00
11/12/2020Craig HallumBoost TargetTop Pick ➝ Buy$25.00 ➝ $35.00
11/12/2020Alliance Global PartnersBoost TargetBuy$28.00 ➝ $40.00
11/12/2020Needham & Company LLCBoost TargetBuy$23.00 ➝ $39.00
11/12/2020Cantor FitzgeraldBoost TargetOverweight$29.00 ➝ $35.00
11/3/2020Needham & Company LLCBoost TargetBuy$21.50 ➝ $23.00
10/5/2020Echelon Wealth PartnersReiterated RatingBuy
9/2/2020Cantor FitzgeraldBoost TargetOverweight$27.00 ➝ $29.00
8/13/2020Stifel NicolausBoost TargetBuy$34.00 ➝ $42.50
8/13/2020Piper SandlerBoost TargetOverweight$12.00 ➝ $20.00
8/13/2020Craig HallumBoost TargetBuy$18.00 ➝ $25.00
8/13/2020Needham & Company LLCBoost TargetBuy$20.50 ➝ $21.50
8/13/2020Cantor FitzgeraldBoost TargetOverweight$21.00 ➝ $27.00
8/5/2020Needham & Company LLCBoost TargetBuy$13.00 ➝ $20.50
7/22/2020Stifel NicolausInitiated CoverageBuy
5/18/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$9.60 ➝ $15.00
5/15/2020Needham & Company LLCBoost TargetBuy$11.00 ➝ $12.25
4/28/2020Needham & Company LLCInitiated CoverageBuy$11.00
3/27/2020Piper SandlerLower TargetOverweight$16.00 ➝ $12.00
2/21/2020LADENBURG THALM/SH SHInitiated CoverageBuy
2/13/2020Cantor FitzgeraldInitiated CoverageNeutral$13.00
1/8/2020Echelon Wealth PartnersReiterated RatingBuy$24.00
11/21/2019Alliance Global PartnersReiterated RatingBuy
9/19/2019Alliance Global PartnersInitiated CoverageBuy
9/13/2019CowenInitiated CoverageOutperform$18.50
8/12/2019Piper Sandler CompaniesInitiated CoverageOverweight ➝ Overweight$13.00
6/10/2019Compass PointInitiated CoverageBuy
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/29/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/26/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/27/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Green Thumb Industries logo
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $11.29
Low: $11.28
High: $11.80

50 Day Range

MA: $13.23
Low: $11.29
High: $15.35

52 Week Range

Now: $11.29
Low: $6.42
High: $16.33

Volume

3,690,000 shs

Average Volume

579,916 shs

Market Capitalization

$2.37 billion

P/E Ratio

47.04

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Green Thumb Industries?

The following equities research analysts have issued research reports on Green Thumb Industries in the last year: Alliance Global Partners, Atb Cap Markets, Needham & Company LLC, Stifel Nicolaus, and Wedbush.
View the latest analyst ratings for GTBIF.

What is the current price target for Green Thumb Industries?

4 Wall Street analysts have set twelve-month price targets for Green Thumb Industries in the last year. Their average twelve-month price target is $39.88, suggesting a possible upside of 253.2%. Stifel Nicolaus has the highest price target set, predicting GTBIF will reach $71.50 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $16.00 for Green Thumb Industries in the next year.
View the latest price targets for GTBIF.

What is the current consensus analyst rating for Green Thumb Industries?

Green Thumb Industries currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GTBIF will outperform the market and that investors should add to their positions of Green Thumb Industries.
View the latest ratings for GTBIF.

What other companies compete with Green Thumb Industries?

Other companies that are similar to Green Thumb Industries include Verano, Inari Medical, Certara, GoodRx and Progyny. Learn More about companies similar to Green Thumb Industries.

How do I contact Green Thumb Industries' investor relations team?

Green Thumb Industries' physical mailing address is 325 West Huron Street, Chicago, IL 60654. The company's listed phone number is 312-471-6720 and its investor relations email address is 0. The official website for Green Thumb Industries is www.gtigrows.com. Learn More about contacing Green Thumb Industries investor relations.